ATE188124T1 - Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren - Google Patents

Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren

Info

Publication number
ATE188124T1
ATE188124T1 AT92924753T AT92924753T ATE188124T1 AT E188124 T1 ATE188124 T1 AT E188124T1 AT 92924753 T AT92924753 T AT 92924753T AT 92924753 T AT92924753 T AT 92924753T AT E188124 T1 ATE188124 T1 AT E188124T1
Authority
AT
Austria
Prior art keywords
cells
virus
preventing
transformed cells
induced diseases
Prior art date
Application number
AT92924753T
Other languages
English (en)
Inventor
David Klatzmann
Original Assignee
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Curie filed Critical Univ Paris Curie
Application granted granted Critical
Publication of ATE188124T1 publication Critical patent/ATE188124T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92924753T 1991-10-30 1992-10-30 Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren ATE188124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9113429 1991-10-30
PCT/FR1992/001017 WO1993008844A1 (fr) 1991-10-30 1992-10-30 Cellules transformees pour la prevention ou le traitement de maladies induites par des virus, notamment retrovirus pathogenes

Publications (1)

Publication Number Publication Date
ATE188124T1 true ATE188124T1 (de) 2000-01-15

Family

ID=9418480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924753T ATE188124T1 (de) 1991-10-30 1992-10-30 Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren

Country Status (7)

Country Link
EP (1) EP0564645B1 (de)
JP (1) JPH06505401A (de)
AT (1) ATE188124T1 (de)
CA (1) CA2099247A1 (de)
DE (1) DE69230491T2 (de)
ES (1) ES2142834T3 (de)
WO (1) WO1993008844A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
KR960703172A (ko) 1993-11-18 1996-06-19 스티븐 제이. 멘토 조건적으로 치사적인 유전자를 활용하기 위한 조성물 및 방법(Compositions and methods for utilizing conditionally lethal genes)
EP0758387B1 (de) * 1994-05-02 2001-12-19 University of Washington Thymidin-kinase-mutanten
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
FR2736931B1 (fr) 1995-07-17 1997-09-19 Univ Paris Curie Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures
ITTO20100633A1 (it) 2010-07-21 2012-01-21 Cnh Italia Spa Meccanismo operativo per un cavo bowden

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
FR2629469B1 (fr) * 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
WO1990011359A1 (en) * 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
FR2651005B1 (fr) * 1989-08-17 1992-01-03 Pasteur Institut Lignees de cellules infectables par un retrovirus et contenant un marqueur activable a l'occasion de l'infection
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy

Also Published As

Publication number Publication date
JPH06505401A (ja) 1994-06-23
DE69230491T2 (de) 2000-08-03
EP0564645B1 (de) 1999-12-29
ES2142834T3 (es) 2000-05-01
EP0564645A1 (de) 1993-10-13
DE69230491D1 (de) 2000-02-03
CA2099247A1 (fr) 1993-05-01
WO1993008844A1 (fr) 1993-05-13

Similar Documents

Publication Publication Date Title
MY138860A (en) Hiv protease inhibitors.
EA199901031A1 (ru) Производные бензимидазола
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
DE69230491D1 (de) Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
ATE199718T1 (de) Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate- aufnahme
ES2182915T3 (es) Procedimiento de purificacion del factor viii
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
ES2151600T3 (es) Derivados de n-(3-amino-2-hidroxibutil)sulfonamida utilizados como inhibidores de proteasa de vih.
ATE412666T1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
FR2388828A1 (fr) 5-iodo-5'-amino-2',5'-didesoxycytidine et medicament contenant cette substance ou un sel de celle-ci
IL82523A0 (en) Microbicidal compositions,their manufacture and drugs containing them
FR2388562A1 (fr) Medicament contenant de la 5'-amino-5'-desoxythymidine ou un sel de cette substance
ATE190492T1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
DE59707067D1 (de) Verfahren zur inaktivierung von lipidumhüllten viren mit lipopeptiden und neue antivirale lipopeptide
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DE69331216D1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
ATE155795T1 (de) Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ES2169033T3 (es) Empleo de la manganeso-superoxidodismutasa (mn-sod) para la elaboracion de medicamentos para el tratamiento de enfermedades, en una dosis pequeña.
ATE189604T1 (de) Extrakte von piliostigma thonningii, deren verwendung und diese enthaltende zubereitungen
DE69434019D1 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties